

Chao Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11913088/publications.pdf>

Version: 2024-02-01

16
papers

395
citations

1040056

9
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

638
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 13-21. | 2.5 | 12 |
| 2 | Pharmacokinetics and Immunogenicity Investigation of a Human Anti-Interleukin-17 Monoclonal Antibody in Non-Naïve Cynomolgus Monkeys. <i>Drug Metabolism and Disposition</i> , 2015, 43, 762-770. | 3.3 | 13 |
| 3 | A phase 1, randomized study to assess the pharmacokinetic comparability of siltuximab derived from two different cell lines in healthy subjects. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 328-334. | 1.6 | 3 |
| 4 | A Novel Approach to Evaluate the Pharmacokinetic Biocomparability of a Monoclonal Antibody Derived from Two Different Cell Lines Using Simultaneous Crossover Design. <i>AAPS Journal</i> , 2014, 16, 125-128. | 4.4 | 3 |
| 5 | Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 358-362. | 2.8 | 186 |
| 6 | Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation-Positive Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 955-961. | 2.0 | 35 |
| 7 | A novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell lines. <i>MAbs</i> , 2013, 5, 150-161. | 5.2 | 4 |
| 8 | Monoclonal antibodies: interspecies scaling with minimal preclinical information. <i>Therapeutic Delivery</i> , 2011, 2, 359-368. | 2.2 | 10 |
| 9 | Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 4436-4440. | 2.2 | 24 |
| 10 | Interaction of Macrolide Antibiotics with Intestinally Expressed Human and Rat Organic Anion-Transporting Polypeptides. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2375-2382. | 3.3 | 44 |
| 11 | Involvement of Intestinal Uptake Transporters in the Absorption of Azithromycin and Clarithromycin in the Rat. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2492-2498. | 3.3 | 34 |
| 12 | Nitric oxide inhibits norepinephrine-induced hepatic vascular responses but potentiates hepatic glucose output. <i>Canadian Journal of Physiology and Pharmacology</i> , 1999, 78, 36-44. | 1.4 | 1 |
| 13 | Blockade of Nitric Oxide Synthase Potentiates the Suppression of Vasodilators by Norepinephrine in the Hepatic Artery. <i>Nitric Oxide - Biology and Chemistry</i> , 1999, 3, 172-179. | 2.7 | 2 |
| 14 | Endogenous inotropic factor-induced endothelium-dependent relaxation of vascular smooth muscle. <i>British Journal of Pharmacology</i> , 1996, 118, 228-232. | 5.4 | 3 |
| 15 | Pharmacokinetics of nitroglycerin and its four metabolites during nitroglycerin transdermal administration. <i>Biopharmaceutics and Drug Disposition</i> , 1994, 15, 179-183. | 1.9 | 6 |
| 16 | Improved gas chromatographic assay for the simultaneous determination of nitroglycerin and its mono- and dinitrate metabolites. <i>Biomedical Applications</i> , 1992, 579, 237-245. | 1.7 | 12 |